Online citations, reference lists, and bibliographies.
← Back to Search

PD‐1 Signaling In Primary T Cells

J. Riley
Published 2009 · Biology, Medicine
Referenced 1 time by Citationsy Users

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Summary:  Programmed death‐1 (PD‐1) is a cell surface molecule that regulates the adaptive immune response. Engagement of PD‐1 by its ligands PD‐L1 or PD‐L2 transduces a signal that inhibits T‐cell proliferation, cytokine production, and cytolytic function. While a great deal is known concerning the biologic roles PD‐1 plays in regulating the primary immune response and in T‐cell exhaustion, comparatively little is known regarding how PD‐1 ligation alters signaling pathways. PD‐1 ligation is known to inhibit membrane‐proximal T‐cell signaling events, while ligation of the related inhibitory molecule cytotoxic T‐lymphocyte antigen‐4 appears to target more downstream signaling pathways. A major obstacle to an in‐depth understanding of PD‐1 signaling is the lack of physiologic models in which to study signal transduction. This review focuses on: (i) signaling pathways altered by PD‐1 ligation, (ii) factors recruited upon PD‐1 phosphorylation, and (iii) exploring the hypothesis that PD‐1 ligation induces distinct signals during various stages of immune‐cell differentiation. Lastly, we describe models to dissect the function of the PD‐1 cytoplasmic tail using primary cells in the absence of agonist antibodies.
This paper references
Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB.
M. Ono (1996)
10.1146/ANNUREV.IMMUNOL.23.021704.115611
The B7 family revisited.
R. Greenwald (2005)
10.1006/CLIM.2002.5277
A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.
A. K. Thomas (2002)
10.1038/ni0702-611
CTLA-4: new insights into its biological function and use in tumor immunotherapy
J. Egen (2002)
10.1016/J.IT.2006.12.001
The road to recovery: translating PD-1 biology into clinical benefit.
J. Riley (2007)
10.1084/JEM.184.1.295
Phosphotyrosines in the killer cell inhibitory receptor motif of NKB1 are required for negative signaling and for association with protein tyrosine phosphatase 1C
A. M. Fry (1996)
10.1073/pnas.231486598
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T. Okazaki (2001)
10.4049/jimmunol.169.10.5441
Evidence That SHIP-1 Contributes to Phosphatidylinositol 3,4,5-Trisphosphate Metabolism in T Lymphocytes and Can Regulate Novel Phosphoinositide 3-Kinase Effectors1
R. Freeburn (2002)
10.1038/ni944
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
N. Watanabe (2003)
10.1002/EJI.1830231029
Ligation of CD28 receptor by B7 induces formation of D‐3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation
S. Ward (1993)
10.1126/science.1158013
Variability and Robustness in T Cell Activation from Regulated Heterogeneity in Protein Levels
O. Feinerman (2008)
10.1002/eji.200535226
Leukocyte‐associated Ig‐like receptor‐1 has SH2 domain‐containing phosphatase‐independent function and recruits C‐terminal Src kinase
A. Verbrugge (2006)
10.1038/nri1131
Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling
C. Rudd (2003)
10.1074/JBC.270.49.29189
Adapter Function of Protein-tyrosine Phosphatase 1D in Insulin Receptor/Insulin Receptor Substrate-1 Interaction (*)
A. Kharitonenkov (1995)
10.1038/nm.1779
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor
Angel Varela-Rohena (2008)
10.4049/jimmunol.168.10.5047
SHP-1- and Phosphotyrosine-Independent Inhibitory Signaling by a Killer Cell Ig-Like Receptor Cytoplasmic Domain in Human NK Cells1
S. Yusa (2002)
10.1016/J.IMMUNI.2007.09.006
Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
E. Wherry (2007)
10.1074/JBC.M502041200
Siglec-5 (CD170) Can Mediate Inhibitory Signaling in the Absence of Immunoreceptor Tyrosine-based Inhibitory Motif Phosphorylation*
T. Avril (2005)
10.1128/MCB.16.3.1189
Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression.
A. Bennett (1996)
10.1093/INTIMM/DXG134
Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment.
A. Verbrugge (2003)
10.1016/J.CELLSIG.2003.08.013
Systematic identification of immunoreceptor tyrosine-based inhibitory motifs in the human proteome.
E. Staub (2004)
10.1016/J.COI.2007.04.012
PD-1 and its ligands in T-cell immunity.
M. Keir (2007)
10.1146/ANNUREV.IMMUNOL.23.021704.115647
Nonreceptor protein-tyrosine phosphatases in immune cell signaling.
L. Pao (2007)
10.4049/jimmunol.174.11.6648
Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo1
T. Ito (2005)
B and T lymphocyte attenuatormediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs
JM Chemnitz (2006)
10.1111/j.1600-065X.2008.00662.x
Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways
B. Fife (2008)
10.1385/IR:35:1:127
Investigations into the regulation and function of the SH2 domain-containing protein-tyrosine phosphatase, SHP-1
F. W. Tsui (2006)
10.4049/jimmunol.177.2.1085
Grb2 and Gads Exhibit Different Interactions with CD28 and Play Distinct Roles in CD28-Mediated Costimulation1
Ryosuke Watanabe (2006)
10.1146/annurev.immunol.26.021607.090331
PD-1 and its ligands in tolerance and immunity.
M. Keir (2008)
10.1002/j.1460-2075.1992.tb05481.x
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y. Ishida (1992)
10.1038/nm1482
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
L. Trautmann (2006)
10.1038/70932
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
H. Dong (1999)
10.1038/351069A0
Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src
Shigeyuki Nada (1991)
10.1007/BF02786326
Regulation of cell signaling by the protein tyrosine phosphatases, CD45 and SHP-1
T. Ulyanova (1997)
10.1084/JEM.181.6.2077
Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling
G. Pani (1995)
10.1074/jbc.273.1.296
Growth Factor Receptor-bound Protein 2 SH2/SH3 Domain Binding to CD28 and Its Role in Co-signaling*
H. H. Kim (1998)
10.1016/J.JHEP.2006.07.009
Turning on the off switch: regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway.
A. Grakoui (2006)
10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9
PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2
LauraL Carter (2002)
10.1038/nature05115
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
C. Day (2006)
10.1006/SMIM.2000.0223
Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling.
J. Zhang (2000)
10.1038/85330
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman (2001)
10.1038/nri2056
Siglecs and their roles in the immune system
P. Crocker (2007)
10.1073/pnas.0510484103
Loss of Siglec expression on T lymphocytes during human evolution
D. H. Nguyen (2006)
10.1074/jbc.273.33.21194
Grb2 Forms an Inducible Protein Complex with CD28 through a Src Homology 3 Domain-Proline Interaction*
K. Okkenhaug (1998)
10.1038/nri727
The B7–CD28 superfamily
A. Sharpe (2002)
10.1016/J.BBMT.2006.10.023
Dendritic cells in transplantation and immune-based therapies.
J. Young (2007)
10.1038/nri1710
Fuel feeds function: energy metabolism and the T-cell response
C. Fox (2005)
10.1016/J.IMMUNI.2007.05.016
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
M. Butte (2007)
10.1038/nbt1070
Directed evolution of human T-cell receptors with picomolar affinities by phage display
Y. Li (2005)
10.1073/pnas.092284399
Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation
M. Diehn (2002)
10.1038/nbt957
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector
Andrea L. Szymczak (2004)
10.4049/jimmunol.164.11.5805
GRID: A Novel Grb-2-Related Adapter Protein That Interacts with the Activated T Cell Costimulatory Receptor CD28
Jonathan Henry Ellis (2000)
10.1074/jbc.R700044200
Phosphoinositide Lipid Phosphatases: Natural Regulators of Phosphoinositide 3-Kinase Signaling in T Lymphocytes*
S. Harris (2008)
10.1084/jem.20021305
A Single Amino Acid Alteration in Cytoplasmic Domain Determines IL-2 Promoter Activation by Ligation of CD28 but Not Inducible Costimulator (ICOS)
Y. Harada (2003)
10.1073/PNAS.93.18.9624
Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness.
U. Lorenz (1996)
10.1038/ni1165
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
H. Probst (2005)
10.1084/jem.20061496
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
C. Petrovas (2006)
10.1016/S1074-7613(02)00323-0
The CD28 signaling pathway regulates glucose metabolism.
K. Frauwirth (2002)
10.1128/MCB.20.22.8513-8525.2000
The Tyrosine Phosphatase SHP-2 Is Required for Sustained Activation of Extracellular Signal-Regulated Kinase and Epithelial Morphogenesis Downstream from the Met Receptor Tyrosine Kinase
C. Maroun (2000)
10.1128/MCB.14.10.6674
Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation.
T. Noguchi (1994)
10.1038/nri1330
Jurkat T cells and development of the T-cell receptor signalling paradigm
R. Abraham (2004)
Cutting Edge: CTLA-4 Ligation Delivers a Unique Signal to Resting Human CD4 T Cells That Inhibits Interleukin-2 Secretion but Allows Bcl-XL Induction
P. Blair (1998)
Evidence that SHIP1 contributes to phosphatidylinositol 3,4,5trisphosphate metabolism in T lymphocytes and can regulate novel phosphoinositide 3-kinase effectors
RW Freeburn (2002)
10.4049/jimmunol.179.8.5301
STAT5 Is Essential for Akt/p70S6 Kinase Activity during IL-2-Induced Lymphocyte Proliferation1
Heather M. Lockyer (2007)
10.1073/pnas.162359999
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors
J. Riley (2002)
10.4049/jimmunol.176.11.6603
B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells That Can Be Initiated by Multiple Phosphotyrosine Motifs1
J. Chemnitz (2006)
10.4049/jimmunol.171.1.166
CD28 and Inducible Costimulatory Protein Src Homology 2 Binding Domains Show Distinct Regulation of Phosphatidylinositol 3-Kinase, Bcl-xL, and IL-2 Expression in Primary Human CD4 T Lymphocytes 1
R. Parry (2003)
10.1128/MCB.25.21.9543-9553.2005
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
R. Parry (2005)
10.1074/JBC.M210552200
SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130*
U. Lehmann (2003)
10.1016/S0968-0004(03)00091-4
The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.
B. Neel (2003)
10.1128/JVI.01812-07
Lentiviral Vectors Encoding Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Receptor Genes Efficiently Convert Peripheral Blood CD8 T Lymphocytes into Cytotoxic T Lymphocytes with Potent In Vitro and In Vivo HIV-1-Specific Inhibitory Activity
A. Joseph (2008)
CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction.
P. Blair (1998)
10.1074/JBC.270.10.5631
Involvement of SH2-containing Phosphotyrosine Phosphatase Syp in Erythropoietin Receptor Signal Transduction Pathways (*)
T. Tauchi (1995)
10.4049/jimmunol.173.2.945
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1
J. Chemnitz (2004)
Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles
J Menke (2007)
10.1128/MCB.20.18.6945-6957.2000
Deficiency of PTEN in Jurkat T Cells Causes Constitutive Localization of Itk to the Plasma Membrane and Hyperresponsiveness to CD3 Stimulation
X. Shan (2000)
10.1073/pnas.0710951105
PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice
T. Yoshida (2008)
10.4049/jimmunol.166.3.1763
Constitutive Association of SHP-1 with Leukocyte-Associated Ig-Like Receptor-1 in Human T Cells1
J. Sathish (2001)
10.1016/J.CELLIMM.2007.02.014
The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function.
E. Lázár-Molnár (2006)
10.1016/j.it.2007.12.002
Novel strategies to eliminate persistent viral infections.
M. Martinic (2008)
10.1016/J.BBRC.2004.09.097
Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j.
J. Sayós (2004)
10.1016/J.BBRC.2006.05.036
Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA.
Maya Gavrieli (2006)
10.1038/nature04444
Restoring function in exhausted CD8 T cells during chronic viral infection
D. Barber (2006)
10.4049/jimmunol.174.9.5884a
B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T cells
M. Hurchla (2005)
10.1016/J.IT.2006.02.001
The PD-1-PD-L pathway in immunological tolerance.
T. Okazaki (2006)
10.1084/jem.20061800
Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
G. Freeman (2006)
10.1038/ni1443
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
A. Sharpe (2007)
10.1182/BLOOD-2004-04-1596
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.
J. Riley (2005)
10.1038/MT.SJ.6300134
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
M. Suhoski (2007)
10.1038/ni1242
Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor
Romain Roncagalli (2005)
10.1093/INTIMM/DXM057
PD-1 and PD-1 ligands: from discovery to clinical application.
T. Okazaki (2007)
10.1126/science.272.5265.1173
Direct Regulation of ZAP-70 by SHP-1 in T Cell Antigen Receptor Signaling
D. Plas (1996)
10.1210/MEND.14.9.0513
Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B.
M. Stofega (2000)
10.1038/383263A0
Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FeγRIIB
M. Ono (1996)
10.1073/PNAS.0505497102
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.
J. Wang (2005)
10.1016/S1074-7613(00)80530-0
LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes.
L. Meyaard (1997)
10.1038/nbt1087
Stable antibody expression at therapeutic levels using the 2A peptide
J. Fang (2005)



This paper is referenced by
10.7554/eLife.03416
Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy
R. C. McPherson (2014)
10.2147/OTT.S224013
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Xianguang Bai (2019)
10.1080/17512433.2016.1236681
Novel immunotherapy in the treatment of advanced non-small cell lung cancer
G. Santabarbara (2016)
10.1586/17474086.2014.958464
The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment
A. Isidori (2014)
10.1016/j.imlet.2017.06.004
Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery.
M. Kalim (2017)
10.24920/003498
Expression of PD1 and BTLA on the CD8+ T Cell and γδT Cell Subsets in Peripheral Blood of Non-Small Cell Lung Cancer Patients
Y. Bao (2019)
10.1007/978-1-60761-980-2_11
Negative Regulators in Cancer Immunology and Immunotherapy
W. Zimmermann (2011)
10.3109/14653249.2010.530649
Tumor vaccines and beyond.
J. Melenhorst (2011)
10.1002/bdrb.21176
An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.
F. M. Poulet (2016)
10.1016/j.immuni.2014.10.013
The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection.
Matthew M. Staron (2014)
10.1189/jlb.1212621
At the Bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy
A. Intlekofer (2013)
10.1080/2162402X.2015.1104448
PD-1 expression conditions T cell avidity within an antigen-specific repertoire
S. Simon (2016)
10.1111/j.1365-2567.2011.03550.x
Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade
S. Henson (2012)
10.1084/jem.20112741
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
T. Yokosuka (2012)
10.1155/2012/926321
Targeting Costimulatory Molecules to Improve Antitumor Immunity
D. Capece (2012)
10.4103/2319-4170.158510
Peptide immunotherapy in experimental autoimmune encephalomyelitis
S. Anderton (2015)
10.3390/cancers12040863
Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients
Eline Berghmans (2020)
10.2174/0929867325666180514114806
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
M. D’Agostino (2018)
10.1097/CJI.0b013e318247a4e7
PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer
J. Dulos (2012)
Lymphocyte adhesion and autoimmunity.
M. Tapia (2014)
Immunity The Regulation of CD 8 + T Cell Exhaustion by FoxO 1 prime therapeutic target for enhancing T cell responses during certain forms of chronic infection and cancer
Matthew M. Staron (2014)
The role of glycosylation in regulatory T-cell biology
Faria Ferreira Cabral (2016)
10.4161/SELF.1.2.11548
Co-inhibitory molecules: Controlling the effectors or controlling the controllers?
G. Thangavelu (2010)
10.20944/preprints202012.0419.v1
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Marc Armengol (2020)
10.1128/MCB.05297-11
Phosphotyrosine-Dependent Coupling of Tim-3 to T-Cell Receptor Signaling Pathways
Judong Lee (2011)
10.4049/jimmunol.1102807
B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation
W. Hobo (2012)
10.3389/fimmu.2018.03061
Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
Kaniel Cassady (2018)
10.1172/JCI96107
PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation
A. Petrelli (2018)
10.2147/TCRM.S78039
Clinical utility of nivolumab in the treatment of advanced melanoma
Ramsey Asmar (2016)
Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy
D. Flies (2011)
10.5072/PRISM/26040
Expanding Antigen-specific Tr1 Cells to Treat Autoimmunity
P. Ambalavanan (2015)
10.1159/000355888
Sepsis-Induced Potentiation of Peritoneal Macrophage Migration Is Mitigated by Programmed Cell Death Receptor-1 Gene Deficiency
A. Ayala (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar